Literature DB >> 9429908

Morphine induces splenocyte apoptosis and enhanced mRNA expression of cathepsin-B.

P C Singhal1, K Reddy, N Franki, V Sanwal, N Gibbons.   

Abstract

Morphine has been demonstrated to modulate immune function. We studied whether morphine modulates apoptosis of splenocytes. Splenocytes were isolated from control and morphine treated rats. Splenocytes isolated from morphine treated rats showed increased percentage (P < 0.001) of apoptosis when compared to splenocytes isolated from untreated rats (control, 4.7 +/- 1.0% apoptotic splenocytes/field vs. morphine, 47.8 +/- 3.4% apoptotic splenocytes/field). These results were further confirmed by gel electrophoresis as well as by end-labeling DNA of splenocytes isolated from control and morphine treated rats. Splenocytes from morphine treated rats showed a classical ladder pattern with integer multiples of 180 base pairs. Splenocytes from morphine treated rats also showed increased mRNA expression of cathepsin-B, a gene associated with active cell death. These results suggest that morphine may also be modulating immune function by enhancing apoptosis of splenocytes.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9429908     DOI： 10.1023/a:1027334122387

Source DB:  PubMed          Journal:  Inflammation        ISSN： 0360-3997            Impact factor:   4.092


  39 in total

1.  The periaqueductal gray matter mediates opiate-induced immunosuppression.

Authors:  R J Weber; A Pert
Journal:  Science       Date:  1989-07-14       Impact factor: 47.728

Review 2.  Protease activation during apoptosis: death by a thousand cuts?

Authors:  S J Martin; D R Green
Journal:  Cell       Date:  1995-08-11       Impact factor: 41.582

Review 3.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

4.  Inhibition of calcium mobilization is an early event in opiate-induced immunosuppression.

Authors:  Y Sei; T McIntyre; E Fride; K Yoshimoto; P Skolnick; P K Arora
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

5.  Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes.

Authors:  R J McDonough; J J Madden; A Falek; D A Shafer; M Pline; D Gordon; P Bokos; J C Kuehnle; J Mendelson
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

6.  Immunomodulatory activity of kappa-, mu-, and delta-selective opioid compounds.

Authors:  T J Rogers; D D Taub; T K Eisenstein; E B Geller; M W Adler
Journal:  NIDA Res Monogr       Date:  1990

7.  Effect of morphine on resistance to infection.

Authors:  E Tubaro; G Borelli; C Croce; G Cavallo; C Santiangeli
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

8.  Morphine pellet-induced immunomodulation in mice: temporal relationships.

Authors:  H U Bryant; E W Bernton; J W Holaday
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

9.  Cathepsin B, a cysteine protease implicated in metastatic progression, is also expressed during regression of the rat prostate and mammary glands.

Authors:  R S Guenette; M Mooibroek; K Wong; P Wong; M Tenniswood
Journal:  Eur J Biochem       Date:  1994-12-01

10.  Periodicity of DNA folding in higher order chromatin structures.

Authors:  J Filipski; J Leblanc; T Youdale; M Sikorska; P R Walker
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598
View more
  6 in total

1.  Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro.

Authors:  J A Gurwell; A Nath; Q Sun; J Zhang; K M Martin; Y Chen; K F Hauser
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Morphine-induced apoptosis in the ventral tegmental area and hippocampus after the development but not extinction of reward-related behaviors in rats.

Authors:  Yasaman Razavi; Shabnam Zeighamy Alamdary; Seyedeh-Najmeh Katebi; Fariba Khodagholi; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2013-11-27       Impact factor: 5.046

Review 3.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

Review 4.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

5.  Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro.

Authors:  Valeriya K Khurdayan; Shreya Buch; Nazira El-Hage; Sarah E Lutz; Susan M Goebel; Indrapal N Singh; Pamela E Knapp; Jadwiga Turchan-Cholewo; Avindra Nath; Kurt F Hauser
Journal:  Eur J Neurosci       Date:  2004-06       Impact factor: 3.386

6.  Effect of μ-opioid agonist DAMGO on surface CXCR4 and HIV-1 replication in TF-1 human bone marrow progenitor cells.

Authors:  Marianne Strazza; Anupam Banerjee; Aikaterini Alexaki; Shendra R Passic; Olimpia Meucci; Vanessa Pirrone; Brian Wigdahl; Michael R Nonnemacher
Journal:  BMC Res Notes       Date:  2014-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.